Prognostic Models in Metastatic Renal Cell Carcinoma

Audreylie Lemelin; Kosuke Takemura; Daniel Y C Heng; Matthew S Ernst

doi:10.1016/j.hoc.2023.04.016

Prognostic Models in Metastatic Renal Cell Carcinoma

Hematol Oncol Clin North Am. 2023 Oct;37(5):925-935. doi: 10.1016/j.hoc.2023.04.016. Epub 2023 Jun 1.

Authors

Audreylie Lemelin¹, Kosuke Takemura¹, Daniel Y C Heng², Matthew S Ernst¹

Affiliations

¹ Department of Oncology, Tom Baker Cancer Centre, University of Calgary, cc 110, 1331 - 29th Street Southwest, Calgary, Alberta T2N 4N2, Canada.
² Department of Oncology, Tom Baker Cancer Centre, University of Calgary, cc 110, 1331 - 29th Street Southwest, Calgary, Alberta T2N 4N2, Canada. Electronic address: Daniel.Heng@albertahealthservices.ca.

PMID: 37270385
DOI: 10.1016/j.hoc.2023.04.016

Abstract

As many new systemic therapy options have recently emerged, the standard of care for patients with metastatic renal cell carcinoma (mRCC) is gradually changing. The increasing complexity of treatment options requires more personalized treatment strategies. This evolution in the systemic therapy landscape comes with a need for validated stratification models that facilitate decision making and patient counseling for clinicians through a risk-adapted approach. This article summarizes the available evidence on risk stratification and prognostic models for mRCC, including the International mRCC Database Consortium and Memorial Sloan Kettering Cancer Center models, as well as their association with clinical outcomes.

Keywords: Kidney neoplasms; Prognosis; Renal cell carcinoma; Risk stratification.

Publication types

Review

MeSH terms

Carcinoma, Renal Cell* / drug therapy
Carcinoma, Renal Cell* / pathology
Humans
Kidney Neoplasms* / drug therapy
Kidney Neoplasms* / pathology
Prognosis